The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Side effects of therapy of hepatitis C and their management
Open accessAbstract
Interferon and ribavirin combination therapy for chronic hepatitis C produces a number of well-described side effects that are dominated by fatigue, influenza-like symptoms, hematologic abnormalities, and neuropsychiatric symptoms. Combination therapy with pegylated interferons (peginterferon alfa-2a and alfa-2b) yields an adverse event profile similar to standard interferon, although the frequency of certain adverse events may vary by preparation. Premature withdrawal from therapy due to adverse events was required in 10% to 14% of participants in registration trials of these agents. Most adverse events were safely and effectively managed by dose reduction using predetermined criteria. The most common indications for dose reduction were hematologic abnormalities, such as anemia and neutropenia, with the latter more frequent in peginterferon treatment arms. Recent data suggest that maintaining adherence to a prescribed treatment regimen can enhance antiviral response. Strategies to maximize adherence are being developed and, in the future, may include early identification of and therapy for depression and the selective use of hematopoietic growth factors to ameliorate hematologic abnormalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Self-citationManns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,465
Poynard, T., Marcellin, P., Lee, S. S., Niederau, C., Minuk, G. S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)07124-4 · Cited by 2,318
(2011) · Hepatogastroenterology · doi:10.5754/hge11589 · Cited by 1,756
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120
McHutchison, J. G., Manns, M., Patel, K., Poynard, T., Lindsay, K. L., Trepo, C., Dienstag, J., Lee, W. M., Mak, C., Garaud, J., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.35950 · Cited by 969
Pegylated interferon-α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data
Glue, P. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.110973 · Cited by 504
Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease
Forton, D. M., Thomas, H. C., Murphy, C. A., Allsop, J. M., Foster, G. R., Main, J., Wesnes, K. A., & Taylor-Robinson, S. D. (2002) · Hepatology · doi:10.1053/jhep.2002.30688 · Cited by 450
De Franceschi, L., Fattovich, G., Turrini, F., Ayi, K., Brugnara, C., Manzato, F., Noventa, F., Stanzial, A. M., Solero, P., & Corrocher, R. (2000) · Hepatology · doi:10.1053/he.2000.5789 · Cited by 446
Cited by
EASL Recommendations on Treatment of Hepatitis C 2018
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.026 · Cited by 2,827
Tanaka, Y., Nishida, N., Sugiyama, M., Kurosaki, M., Matsuura, K., Sakamoto, N., Nakagawa, M., Korenaga, M., Hino, K., Hige, S., et al. (2009) · Nature Genetics · doi:10.1038/ng.449 · Cited by 2,141
Diagnosis, management, and treatment of hepatitis C†
Strader, D. B., Wright, T., Thomas, D. L., & Seeff, L. B. (2004) · Hepatology · doi:10.1002/hep.20119 · Cited by 1,709
EASL Recommendations on Treatment of Hepatitis C 2015
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.03.025 · Cited by 1,156
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
(2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.023 · Cited by 1,088
EASL Recommendations on Treatment of Hepatitis C 2016
(2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.09.001 · Cited by 985
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
(2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.003 · Cited by 855
Treating viral hepatitis C: efficacy, side effects, and complications
Manns, M. P., Wedemeyer, H., & Cornberg, M. (2006) · Gut · doi:10.1136/gut.2005.076646 · Cited by 659
Management of hepatitis B: Summary of a clinical research workshop†
Hoofnagle, J. H., Doo, E., Liang, T. J., Fleischer, R., & Lok, A. S. F. (2007) · Hepatology · doi:10.1002/hep.21627 · Cited by 628
Peginterferon and Ribavirin for Chronic Hepatitis C
Hoofnagle, J. H., & Seeff, L. B. (2006) · New England Journal of Medicine · doi:10.1056/nejmct061675 · Cited by 476
Chen, L., Borozan, I., Feld, J., Sun, J., Tannis, L.-L., Coltescu, C., Heathcote, J., Edwards, A. M., & McGilvray, I. D. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.01.059 · Cited by 453
American Gastroenterological Association Technical Review on the Management of Hepatitis C
Dienstag, J. L., & McHutchison, J. G. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.010 · Cited by 384
Manns, M., Marcellin, P., Poordad, F., de Araujo, E. S. A., Buti, M., Horsmans, Y., Janczewska, E., Villamil, F., Scott, J., Peeters, M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60538-9 · Cited by 376
Rein, D. B., Smith, B. D., Wittenborn, J. S., Lesesne, S. B., Wagner, L. D., Roblin, D. W., Patel, N., Ward, J. W., & Weinbaum, C. M. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-4-201202210-00378 · Cited by 302
Academic Health Center Management of Chronic Diseases through Knowledge Networks: Project ECHO
Arora, S., Geppert, C. M. A., Kalishman, S., Dion, D., Pullara, F., Bjeletich, B., Simpson, G., Alverson, D. C., Moore, L. B., Kuhl, D., et al. (2007) · Academic Medicine · doi:10.1097/acm.0b013e31802d8f68 · Cited by 295
Kwong, A. D., Kauffman, R. S., Hurter, P., & Mueller, P. (2011) · Nature Biotechnology · doi:10.1038/nbt.2020 · Cited by 274
Zeuzem, S. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-5-200403020-00033 · Cited by 261
Side effects of therapy for chronic hepatitis C
Russo, M. W., & Fried, M. W. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00394-9 · Cited by 261
Self-citationKang, J. S., DeLuca, P. P., & Lee, K. C. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210902907847 · Cited by 252
Fahey, B., Hickey, B., Kelleher, D., O’Dwyer, A.-M., & O’Mara, S. M. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.05.005 · Cited by 43
Chronic hepatitis C and antiviral treatment regimens: Where can psychology contribute?
Evon, D. M., Golin, C. E., Fried, M. W., & Keefe, F. J. (2013) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0029030 · Cited by 32
Self-citationFumaz, C. R., Muñoz-Moreno, J. A., Ballesteros, A. L., Paredes, R., Ferrer, M. J., Salas, A., Fuster, D., Masmitjà, E., Pérez-Álvarez, N., Gómez, G., et al. (2007) · AIDS Care · doi:10.1080/09540120600645539 · Cited by 30
Evon, D. M., Golin, C. E., Ruffin, R., & Fried, M. W. (2017) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2017.03.008 · Cited by 5
“Until 2014, treatment consisted of peginterferon/ribavirin (PegIFN/ RBV) and caused numerous side effects, leading to nonadherence and premature treatment discontinuations [11,12].”
Self-citation
Metadata
- Authors
- Fried, M. W.
- Venue
- Hepatology
- Published
- 2002-11
- Volume
- 36
- Issue
- Supplement 1
- Pages
- S237-S244
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W4244312606
- Cited by
- 556
- References
- 38
- FWCI
- 12.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.